

09/837998

Search results

Refine Search

Search Results -

Terms	Documents
E3L near10 attenuat\$	4

Database:

US Pre-Grant Publication Full-Text Database
 US Patents Full-Text Database
 US OCR Full-Text Database
 EPO Abstracts Database
 JPO Abstracts Database
 Derwent World Patents Index
 IBM Technical Disclosure Bulletins

Search:

L7

Refine Search

Recall Text

Clear

Interrupt

Search History

DATE: Tuesday, December 30, 2003 [Printable Copy](#) [Create Case](#)

Set Name	Query	Hit Count	Set Name result set
side by side			
DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD; PLUR=YES; OP=OR			
<u>L7</u>	E3L near10 attenuat\$	4	<u>L7</u>
<u>L6</u>	L5 and vaccinia near10 expression near5 vector\$	3	<u>L6</u>
<u>L5</u>	L4 and expression near5 vector\$	6	<u>L5</u>
<u>L4</u>	L3 and E3L near10 (dsRNA\$ or double near strand\$ near RNA\$ or RNA\$)	11	<u>L4</u>
<u>L3</u>	L2 and (reduc\$ or alter\$) near10 pathogen\$	13	<u>L3</u>
<u>L2</u>	L1 and E3L near10 delet\$	20	<u>L2</u>
<u>L1</u>	vaccinia and E3L	75	<u>L1</u>

END OF SEARCH HISTORY

[Generate Collection](#)[Print](#)**Search Results - Record(s) 1 through 75 of 75 returned.**

-
- ☐ 1. 20030215425. 07 Dec 01. 20 Nov 03. Epitope synchronization in antigen presenting cells. Simard, John J. L., et al. 424/93.7; 424/85.1 424/85.2 435/372 514/44 536/23.1 A61K045/00 A61K038/19 A61K038/20 A61K048/00 C07H021/02 C07H021/04 C12N005/08.
-
- ☐ 2. 20030211964. 16 Dec 02. 13 Nov 03. Method of inhibiting pathogenicity of infectious agents. Jacobs, Bertram L., et al. 514/1; 435/6 A61K031/00 C12Q001/68.
-
- ☐ 3. 20030198623. 09 Oct 02. 23 Oct 03. Recombinant virus immunotherapy. Paoletti, Enzo, et al. 424/93.2; 435/235.1 435/456 514/44 A61K048/00 C12N015/863 C12N007/00.
-
- ☐ 4. 20030165465. 13 Jun 02. 04 Sep 03. Treatment of neoplasms with viruses. Roberts, Michael S., et al. 424/93.2; 435/235.1 435/456 A61K048/00 C12N015/86 C12N007/00.
-
- ☐ 5. 20030157131. 09 Dec 02. 21 Aug 03. Interferon inducing genetically engineered attenuated viruses. Egorov, Andrei, et al. 424/209.1; 424/199.1 435/320.1 435/69.1 C12P021/06 A61K039/12 A61K039/145 C12N015/00 C12N015/09 C12N015/63 C12N015/70 C12N015/74.
-
- ☐ 6. 20030153083. 15 Nov 02. 14 Aug 03. Selective killing of cells by activation of double-stranded RNA dependent protein kinase-pkr. Shir, Alexei, et al. 435/456; 435/375 435/458 514/44 A61K048/00 C12N015/861 C12N015/88.
-
- ☐ 7. 20030148973. 17 May 02. 07 Aug 03. MAGE-A1 peptides for treating or preventing cancer. Emtage, Peter, et al. 514/44; 424/185.1 424/93.2 536/23.1 C07H021/04 A61K048/00 A61K039/00.
-
- ☐ 8. 20030144226. 27 Mar 02. 31 Jul 03. Method for selective inactivation of viral replication. Miles, Vincent J., et al. 514/44; 435/5 435/6 C12Q001/70 C12Q001/68 A61K048/00.
-
- ☐ 9. 20030138808. 20 Aug 02. 24 Jul 03. Expression vectors encoding epitopes of target-associated antigens. Simard, John J.L., et al. 435/6; 536/23.2 C12Q001/68 C07H021/04.
-
- ☐ 10. 20030113919. 15 Aug 02. 19 Jun 03. Immunogenic targets for melanoma. Emtage, Peter, et al. 435/456; 435/235.1 435/320.1 C12N015/86 C12N007/00.
-
- ☐ 11. 20030086906. 04 Nov 02. 08 May 03. Method of inducing an immune response using vaccinia virus recombinants. Mastrangelo, Michael J., et al. 424/93.2; 435/235.1 435/456 514/44 A61K048/00 C12N007/00 C12N015/869.
-
- ☐ 12. 20030084471. 22 Jan 02. 01 May 03. Methods and compositions for RNA interference. Beach, David, et al. 800/278; 435/455 A01H005/00 C12N015/85.
-
- ☐ 13. 20030083305. 10 Oct 02. 01 May 03. Viral interferon antagonists and uses therefor. Palese, Peter, et al. 514/44; 424/93.2 A61K048/00.
-
- ☐ 14. 20030082204. 13 Sep 01. 01 May 03. Poxvirus-canine distemper virus (CDV) recombinants and compositions and methods employing the recombinant. Paoletti, Enzo, et al. 424/199.1; 424/186.1

424/212.1 424/213.1 424/232.1 435/235.1 435/236 435/320.1 435/69.3 530/350 C12N015/09
A61K039/165 A61K039/275 C12N007/00 C12N007/04 C12N015/63 C12N015/74 C07K014/00
A61K039/12 A61K039/285 C12N015/00 C07K001/00 A61K039/175 C12N007/01 C12N015/70
C07K017/00.

☐ 15. 20030074691. 09 Oct 02. 17 Apr 03. Resistance to viruses and viroids in transgenic plants and animals expressing dsRNA-binding protein. Roth, Don Allen, et al. 800/280; 424/208.1 A61K039/21 A01H001/00.

☐ 16. 20030064077. 26 Jul 01. 03 Apr 03. Recombinant poxvirus cytomegalovirus, compositions, and uses. Paoletti, Enzo, et al. 424/199.1; 424/204.1 424/230.1 424/232.1 435/235.1 435/320.1 530/300 530/388.1 536/23.72 C12N015/09 A61K038/00 C07K005/00 A61K039/245 A61K039/25 A61K039/285 C12P021/08 C12N015/74 C07K007/00 C07K017/00 C07H021/04.

☐ 17. 20030049651. 05 Mar 02. 13 Mar 03. Tumor associated proteins. Luo, Liu-Ying, et al. 435/6; 435/183 435/320.1 435/325 435/69.1 530/388.26 536/23.2 C12Q001/68 C07H021/04 C12N009/00 A61K039/00 C12P021/02 C12N005/06 C07K016/40.

☐ 18. 20030044384. 15 Jan 02. 06 Mar 03. Treatment of neoplasms with viruses. Roberts, Michael S., et al. 424/93.2; 435/235.1 435/456 A61K048/00 C12N007/00 C12N015/86.

☐ 19. 20030013076. 02 Mar 01. 16 Jan 03. Parapoxvirus vectors. Robinson, Anthony J., et al. 435/5; 435/320.1 435/325 530/351 536/23.5 536/23.7 536/23.72 C12N015/00 C12Q001/70 C07H021/04 C12N015/09 C07K001/00 C07K014/00 C07K017/00 C12N005/00 C12N015/74.

☐ 20. 20020187465. 01 May 02. 12 Dec 02. Viruses for the treatment of cellular proliferative disorders. Coffey, Matthew C., et al. 435/5; 435/235.1 435/91.1 536/23.72 C12Q001/70 C07H021/04 C12P019/34 C12N007/00 C12N007/01.

☐ 21. 20020168344. 15 Feb 02. 14 Nov 02. Sensitization of chemotherapeutic agent resistant neoplastic cells with a virus. Coffey, Matthew C., et al. 424/93.2; 424/649 424/85.5 514/110 514/251 514/34 514/410 514/449 514/50 A61K048/00 A61K038/21 A61K031/704 A61K031/66 A61K031/525.

☐ 22. 20020165194. 28 Mar 02. 07 Nov 02. Method for selective inactivation of viral replication. Miles, Vincent J., et al. 514/44; 435/456 A61K048/00 C12N015/86.

☐ 23. 20020162126. 24 May 01. 31 Oct 02. Methods and compositions for RNA interference. Beach, David, et al. 800/8; 435/455 514/44 A01K067/00 A61K048/00 C12N015/87.

☐ 24. 20020160977. 28 Mar 02. 31 Oct 02. Method for selective inactivation of viral replication. Miles, Vincent J., et al. 514/44; 435/5 A61K048/00 C12Q001/70.

☐ 25. 20020160976. 22 Mar 02. 31 Oct 02. Method for selective inactivation of viral replication. Miles, Vincent J., et al. 514/44; 435/5 A61K048/00 C12Q001/70.

☐ 26. 20020160393. 28 Dec 01. 31 Oct 02. Double-stranded RNA-mediated gene suppression. Symonds, Geoffrey P., et al. 435/6; 435/455 536/23.1 C12Q001/68 C07H021/02 C12N015/87.

☐ 27. 20020155569. 07 Mar 01. 24 Oct 02. Regulation of gene expression through manipulation of mRNA splicing and its uses. Kaempfer, Raymond, et al. 435/194; 514/44 536/23.2 A61K048/00 C07H021/04 C12N009/12.

-
- ☐ 28. 20020155529. 19 Apr 01. 24 Oct 02. Viral vectors having reduced virulence. Jacobs, Bertram, et al. 435/69.1; 435/320.1 435/456 C12P021/02 C12N015/86.
-
- ☐ 29. 20020155431. 05 Oct 01. 24 Oct 02. Novel screening methods to identify agents that selectively inhibit hepatitis C virus replication. Katze, Michael G., et al. 435/5; 435/15 C12Q001/70 C12Q001/48.
-
- ☐ 30. 20020110565. 22 Jun 01. 15 Aug 02. Viral vectors having enhanced effectiveness with reduced virulence. Jacobs, Bertram, et al. 424/199.1; 424/232.1 424/93.2 435/235.1 435/320.1 435/456 A61K048/00 A61K039/12 C12N015/86 C12N007/00 A01N063/00 A61K039/275 A61K039/285 C12N007/01 C12N015/00 C12N015/09 C12N015/63 C12N015/70 C12N015/74.
-
- ☐ 31. 20020090608. 10 Apr 01. 11 Jul 02. Screening methods for identifying viral proteins with interferon antagonizing functions and potential antiviral agents. Palese, Peter M., et al. 435/5; 424/204.1 435/346 435/7.2 536/25.32 C12Q001/70 G01N033/53 G01N033/567 C07H021/00 C07H021/02 C07H021/04 A61K039/12 C12N005/00 C12N005/06 C12N005/12.
-
- ☐ 32. 20020061298. 15 Nov 01. 23 May 02. Method for optimally delivering virus to a solid tumor mass. Coffey, Matthew C., et al. 424/93.21; 435/235.1 A61K048/00 C12N007/01.
-
- ☐ 33. 20020028195. 28 Sep 01. 07 Mar 02. Viruses for the treatment of cellular proliferative disorders. Coffey, Matthew C., et al. 424/93.21; 424/131.1 424/231.1 424/464 435/235.1 514/9 536/23.72 A61K048/00 A61K039/395 A61K038/13 C07H021/04 A01N063/00 C12N007/00.
-
- ☐ 34. 20010048919. 03 May 01. 06 Dec 01. Virus clearance of neoplastic cells from mixed cellular compositions. Morris, Donald, et al. 424/93.21; 435/372 435/456 A61K048/00 C12N005/08 C12N015/86.
-
- ☐ 35. 6667152. 22 Mar 02; 23 Dec 03. Method for selective inactivation of viral replication. Miles; Vincent J., et al. 435/5; 435/320.1 435/326 435/4 435/455 435/456 435/6 435/7.1. C12Q001/68 C12Q001/70 C12N015/63.
-
- ☐ 36. 6649157. 28 Sep 01; 18 Nov 03. Viruses for the treatment of cellular proliferative disorders. Coffey; Matthew C., et al. 424/93.1; 424/205.1 424/231.1 435/236 435/239 435/5 435/7.23 435/91.33 435/91.4. C12Q001/70 C12N007/01 C12N007/00 A61K033/574 A61K039/245.
-
- ☐ 37. 6641816. 09 Mar 01; 04 Nov 03. Use of poxviruses as enhancer of specific immunity. Chevalier; Michel, et al. 424/191.1; 424/205.1 424/206.1 424/207.1 424/232.1 424/93.2 435/236 435/320.1. A61K039/12 A61K039/275 A61K039/285 C12N007/01 C12N007/04.
-
- ☐ 38. 6635416. 10 Apr 01; 21 Oct 03. Screening methods for identifying viral proteins with interferon antagonizing functions and potential antiviral agents. Palese; Peter M., et al. 435/5; 435/235.1 435/236 435/29. C12Q001/70 C12Q001/02 C12N007/00.
-
- ☐ 39. 6632438. 26 Jul 01; 14 Oct 03. Recombinant poxvirus cytomegalovirus, compositions, and uses. Paoletti; Enzo, et al. 424/199.1; 424/204.1 424/230.1 424/232.1 435/235.1 435/320.1 530/300 530/388.1 536/23.72. A61K039/12 A61K039/245 A61K038/00 C12N015/00 C07H021/04.
-
- ☐ 40. 6623961. 28 Mar 02; 23 Sep 03. Method for selective inactivation of viral replication. Miles; Vincent J., et al. 435/370; 435/243 435/252.3 435/254.1 435/254.11 435/320.1 435/325 435/366

536/23.1 536/23.2 536/23.72 536/24.1. C12N005/10 C12N001/21 C12N001/19.

☐ 41. 6596268. 09 Nov 00; 22 Jul 03. Viruses for the treatment of cellular proliferative disorders. Coffey; Matthew C., et al. 424/93.2; 424/142.1 424/9.1 424/9.32 424/93.1 424/93.21 424/93.3 424/93.6 435/236 435/339 435/5 435/7.23 435/91.32 435/91.33 435/91.4 435/91.42 514/11. A61K048/00 C12Q001/70 C12N007/04 C12N005/06 G01N033/374.

☐ 42. 6579674. 28 Mar 02; 17 Jun 03. Method for selective inactivation of viral replication. Miles; Vincent J., et al. 435/5; 435/6 435/7.1 435/7.2 435/7.21 435/7.5 435/7.92. C12Q001/68 C12Q001/70.

☐ 43. 6573079. 11 Jun 99; 03 Jun 03. Methods and interferon deficient substrates for the propagation of viruses. Palese; Peter, et al. 435/235.1; 424/93.6 435/237 435/239. C12N007/00.

☐ 44. 6537594. 24 Mar 00; 25 Mar 03. Vaccinia virus comprising cytokine and/or tumor associated antigen genes. Paoletti; Enzo, et al. 424/93.2; 424/191.1 424/93.6 435/320.1 435/69.1 435/69.3 435/69.5 435/69.51 435/69.52 435/70.1 435/70.3 514/44. A61F002/00.

☐ 45. 6475999. 19 Jun 00; 05 Nov 02. Method of inducing an immune response using vaccinia virus recombinants. Mastrangelo; Michael J., et al. 514/44; 435/320.1 435/325 435/455. A61K048/00 A61K031/00 C12N005/02 C12N015/74 C12N015/63.

☐ 46. 6468544. 11 Jun 99; 22 Oct 02. Interferon inducing genetically engineered attenuated viruses. Egorov; Andrei, et al. 424/209.1; 424/199.1 435/320.1 435/69.1. A61K039/145 C12N015/63 C12N015/66 C12N015/86.

☐ 47. 6372455. 19 Apr 01; 16 Apr 02. Recombinant vaccinia viral vectors. Jacobs; Bertram, et al. 435/69.1; 435/320.1 435/5 536/23.72. C12P021/06 C12Q001/70 C12N015/00 C07H021/04.

☐ 48. 6326151. 25 Feb 00; 04 Dec 01. Screening methods to identify agents that selectively inhibit hepatitis C virus replication. Katze; Michael G., et al. 435/6; 435/254.11 435/254.21 435/375. C12Q001/68.

☐ 49. 6309647. 15 Jul 99; 30 Oct 01. Poxvirus--canine distemper virus (CDV) or measles virus recombinants and compositions and methods employing the recombinants. Paoletti; Enzo, et al. 424/199.1; 424/186.1 424/212.1 424/213.1 435/235.1 435/320.1 435/69.3 530/350. A61K039/275 A61K039/285 A61K039/165 A61K039/175 C12N007/01.

☐ 50. 6287570. 23 Nov 98; 11 Sep 01. Vaccine against swine influenza virus. Foley; Patricia L.. 424/199.1; 424/232.1 424/93.1 424/93.2 435/235.1. A61K039/12 A61K039/285 C12N007/01.

☐ 51. 6267965. 26 May 98; 31 Jul 01. Recombinant poxvirus--cytomegalovirus compositions and uses. Paoletti; Enzo, et al. 424/199.1; 424/204.1 424/230.1 424/232.1 435/235.1 435/320.1 530/300 530/388.1 536/23.72. A61K039/12 A61K039/245 A61K038/00 C12N015/00 C07H021/04.

☐ 52. 6265189. 02 Jun 95; 24 Jul 01. Pox virus containing DNA encoding a cytokine and/or a tumor associated antigen. Paoletti; Enzo, et al. 435/70.1; 435/320.1 435/69.1 435/70.3. C12P021/04 C12N015/00.

☐ 53. 6183752. 05 Feb 97; 06 Feb 01. Restenosis/atherosclerosis diagnosis, prophylaxis and therapy. Epstein; Stephen E., et al. 424/199.1; 424/230.1 424/277.1 424/93.2 435/320.1 514/44. A61K039/245 A61K039/275 C12N015/38 C12N015/12.

-
- ☐ 54. 6156496. 08 Sep 97; 05 Dec 00. Method for selective inactivation of viral replication. Miles; Vincent J., et al. 435/5; 435/325 435/455 435/6 435/7.1 514/44 536/23.1 536/24.5. C12Q001/68 C12Q001/70 C07H021/04.
-
- ☐ 55. 6130066. 15 May 98; 10 Oct 00. Vectors having enhanced expression and methods of making and uses thereof. Tartaglia; James, et al. 435/69.1; 435/320.1 435/91.41 536/23.72. C12P021/06.
-
- ☐ 56. 6093700. 20 Feb 97; 25 Jul 00. Method of inducing an immune response using vaccinia virus recombinants encoding GM-CSF. Mastrangelo; Michael J., et al. 514/44; 435/320.1. A61K048/00 C12N015/00.
-
- ☐ 57. 6030785. 05 Mar 98; 29 Feb 00. Screening methods to identify agents that selectively inhibit hepatitis C virus replication. Katze; Michael G., et al. 435/6; 435/254.21 435/375. C12Q001/68.
-
- ☐ 58. 6004777. 12 Mar 97; 21 Dec 99. Vectors having enhanced expression, and methods of making and uses thereof. Tartaglia; James, et al. 435/69.1; 435/320.1 435/91.41 536/23.1 536/23.72. C12P021/00 C12N015/63 C12N015/66 C12N015/11.
-
- ☐ 59. 5997878. 05 Jun 96; 07 Dec 99. Recombinant poxvirus-cytomegalovirus, compositions and uses. Paoletti; Enzo, et al. 424/199.1; 424/230.1 424/232.1 435/235.1 435/320.1 435/69.1 435/69.3. A61K039/245 A61K039/285 C12N015/00 C12N007/01.
-
- ☐ 60. 5990388. 07 Jun 95; 23 Nov 99. Resistance to viruses and viroids in transgenic plants and animals expressing dsRNA-binding protein. Roth; Don Allen, et al. 800/301; 435/320.1 800/280 800/317.2 800/317.3. C12N005/00 C12N015/00 A01H001/04.
-
- ☐ 61. 5990091. 12 Mar 97; 23 Nov 99. Vectors having enhanced expression, and methods of making and uses thereof. Tartaglia; James, et al. 514/44; 424/93.2 435/320.1 435/69.1 435/91.4 435/91.41. C12N015/67 C12N015/86 A61K048/00.
-
- ☐ 62. 5942235. 02 Jun 95; 24 Aug 99. Recombinant poxvirus compositions and methods of inducing immune responses. Paoletti; Enzo. 424/232.1; 424/199.1 424/93.2 435/320.1 435/456. A61K039/275 A61K039/12 A61K048/00 C12N015/00.
-
- ☐ 63. 5833975. 19 Jan 94; 10 Nov 98. Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence. Paoletti; Enzo, et al. 424/93.2; 435/320.1 435/456 435/69.3 435/69.5 435/69.51 435/69.52. A61K048/00 C12N015/00 C12N015/86.
-
- ☐ 64. 5795713. 04 Feb 97; 18 Aug 98. Methods for identifying inducers and inhibitors of programmed cell death. Roizman; Bernard, et al. 435/5; 435/15 435/21. C12Q001/42 C12Q001/48 C12Q001/70.
-
- ☐ 65. 5738985. 01 Apr 94; 14 Apr 98. Method for selective inactivation of viral replication. Miles; Vincent J., et al. 435/5; 435/254.2 435/6 435/7.1. C12Q001/02 C12Q001/68 C12Q001/70.
-
- ☐ 66. JP02003230379A. 04 Jun 96. 19 Aug 03. RESISTIVITY TO VIRUS AND VIROID IN TRANSGENIC PLANT AND ANIMAL HOST EXPRESSING DOUBLE STRAND RNA-BINDING PROTEIN. ROTH, DON ALLEN, et al. C12N007/00; A61P031/12 C12N015/09 A61K035/76 A61K038/00 A61K048/00.
-

- ☐ 67. WO003023040A2. 11 Sep 02. 20 Mar 03. VACCINIA VIRUS MVA-E3L-KNOCK-OUT-MUTANTS AND USE THEREOF. ERFLE, VOLKER, et al. C12N015/86; C12N007/00 A61K038/21 A61K038/48 A61K039/00.
-
- ☐ 68. US20030044384A. Infecting a neoplasm in a human with a virus comprises administering an interferon-sensitive, replication-competent clonal RNA virus, vaccinia virus or DNA virus to the human. GROENE, W S, et al. A61K048/00 C12N007/00 C12N015/86.
-
- ☐ 69. WO2003023040A. New vaccinia virus MVA-E3L knock-out mutant, useful for generating recombinant MVA viruses or host cells, comprises an inactivated MVA ORF 050L gene in its viral genome. ERFLE, V, et al. A61K038/21 A61K038/48 A61K039/00 C12N005/10 C12N007/00 C12N007/04 C12N015/63 C12N015/86.
-
- ☐ 70. US20020155529A. New expression vector comprising a vaccinia virus having a deletion of the region encoding amino acids 184-190 of the E3L gene product, useful for making recombinant gene products, as veterinary or human vaccines, or anticancer agents. JACOBS, B, et al. A61K038/00 A61K048/00 C12N015/63 C12N015/64 C12N015/86 C12N015/863 C12P021/00 C12P021/02.
-
- ☐ 71. US 6372455B. Vaccinia virus for use as a delivery system for gene products, as a human or veterinary vaccine and as an anticancer agent, comprises that the E3L gene is replaced by a gene encoding an E3L homolog from the orf virus. JACOBS, B, et al. C07H021/04 C12N000/00 C12N015/00 C12P021/06 C12Q001/70.
-
- ☐ 72. US20020110565A. Vaccinia virus with amino acids deleted from the E3L gene product, which reduces virulence and improves efficacy, useful as a vaccine. BRANDT, T A, et al. A01N063/00 A61K039/12 A61K039/275 A61K039/285 A61K048/00 C07H021/02 C07H021/04 C12N007/00 C12N007/01 C12N015/00 C12N015/09 C12N015/39 C12N015/63 C12N015/64 C12N015/70 C12N015/74 C12N015/86 C12P021/06.
-
- ☐ 73. WO 200062735A. Treating neoplasms including cancer and solid tumors in a mammal comprises administering interferon-sensitive, replication-competent clonal RNA or DNA viruses such as paramyxovirus and herpesvirus. GROENE, W S, et al. A61K000/00 A61K031/282 A61K031/573 A61K035/76 A61K038/00 A61K038/17 A61K045/00 A61K048/00 A61P035/00 A61P035/02 A61P035/04 A61P043/00 C07J005/00 C12N007/00 C12N015/86.
-
- ☐ 74. WO 9955910A. Inducing apoptosis in a target cell useful for treating cancer. JACOBS, B L. A61K048/00 C07H021/02 C07H021/04 C12N015/85 C12N015/86 C12Q001/68.
-
- ☐ 75. WO 9918799A. Treating tumours by infection with interferon-sensitive viruses - effective against large tumours that do not respond to chemotherapy. GROENE, W S, et al. A01N063/00 A61K038/21 A61K048/00 A61P035/00 C12N007/02 C12N007/04 C12N015/01 G01N033/15 G01N033/50.

[Generate Collection](#)[Print](#)

Terms	Documents
vaccinia and E3L	75

[Prev Page](#)[Next Page](#)[Go to Doc#](#)

 **PALM INTRANET**Day : Tuesday
Date: 12/30/2003

Time: 11:58:16

Inventor Name Search

Enter the **first few letters** of the Inventor's Last Name.
Additionally, enter the **first few letters** of the Inventor's First name.

Last Name**First Name**

To go back use Back button on your browser toolbar.

Back to [PALM](#) | [ASSIGNMENT](#) | [OASIS](#) | [Home page](#)

PALM INTRANET

Day : Tuesday
Date: 12/30/2003

Time: 11:58:16

Inventor Name Search

Enter the **first few letters** of the Inventor's Last Name.
Additionally, enter the **first few letters** of the Inventor's First name.

Last Name**First Name**

To go back use Back button on your browser toolbar.

Back to [PALM](#) | [ASSIGNMENT](#) | [OASIS](#) | [Home page](#)